Shares of Relay Therapeutics, Inc. (NASDAQ:RLAY) have earned a consensus rating of “Buy” from the eight analysts that are presently covering the stock, MarketBeat Ratings reports. Two investment analysts have rated the stock with a hold recommendation and six have given a buy recommendation to the company. The average twelve-month price objective among brokerages that […]
